Filing Flows › Ocugen (OCGN) › R&D spending
Ocugen (OCGN) R&D spending by quarter
Ocugen's R&D spending was $12.5M in Q3 2026 (third quarter 2026), +17% from Q2 2026. Over the last 6 quarters it ranged from $8.4M (Q2 2025) to $12.5M (Q3 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $12.5M | +17% | +12% |
| Q2 2026 | $10.7M | -5% | +27% |
| Q1 2026 | $11.3M | +1% | +18% |
| Q3 2025 | $11.1M | +33% | — |
| Q2 2025 | $8.4M | -12% | — |
| Q1 2025 | $9.5M | — | — |
Q3 2026 at a glance
Ocugen, Q3 2026: revenue $2.0M (+11% year over year), operating margin -909.9%, net loss $3.6M, operating cash flow −$15.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is Ocugen's R&D spending?
Ocugen's R&D spending was $12.5M in Q3 2026 (third quarter 2026), +17% from Q2 2026.
How has Ocugen's R&D spending changed?
Over the last 6 quarters it ranged from $8.4M (Q2 2025) to $12.5M (Q3 2026).